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Abstract 
Although some vaccines and antibiotics have been 
very effective in preventing and treating respiratory dis-
ease, they have not been fully satisfactory. Recently, 
components of the innate immune system have been in-
creasingly appreciated for their role in host defense 
against microbial pathogens. These molecules include 
lysozyme and lactoferrin, but recent work in cattle, 
sheep, man and other species have identified new classes 
of peptides expressed by respiratory epithelial cells that 
have potent microcidal activity in nanogram quantities. 
These peptides, termed antimicrobial peptides (AMP), 
include defensins, cathelicidins and anionic peptides. 
Some are expressed continuously whereas expression 
of others is stimulated by infection/inflammation. In 
calves, we have found that two AMP from the defensin 
family, tracheal antimicrobial peptide (TAP) and lingual 
antimicrobial peptide (LAP), are expressed in the new-
born and increased in response to Mannheimia (Pas-
teurella) haemolytica infection. In contrast, sheep beta 
defensin-1 (SBD-1) is not induced by infection and, in 
fact , appears decreased during viral infection with 
paramyxovirus-3 (Pl-3). Decreased SBD-1 by Pl-3 may 
increase the lung's susceptibility to secondary infections 
or re-infections. Other innate defense molecules include 
proteins released with lung surfactant. Surfactant pro-
tein A and D (SAD) can opsonize and aggregate respira-
tory syncytial virus (RSV) and activate alveolar 
macrophages. Preliminary work suggests that chronic 
bacterial infections result in reduced SpA and SpD ex-
pression and we are currently assessing SAD expres-
sion in response to PI-3 and RSV. A long-term goal of 
our work is to identify ways to up-regulate expression 
of AMP and/or surfactant proteins in the neonate and 
at times of stress in older animals in order to reduce 
microbial colonization. Other investigators are seeking 
ways to utilize AMP's as a new class of antibiotics . 
Key words: anionic peptides, antimicrobial pep-
tides, cathelicidins, defensins, epithelia, innate immu-
nity, pneumonia, respiratory tract, shipping fever 
Introduction 
Respiratory disease is a serious cause of death and 
economic loss in cattle and sheep. 1·15•25 Of every 1000 
cattle that enter feedlots, an average of 12.6 die, and 
respiratory disease accounts for 57 .1 % of these deaths 
and most deaths occur within 45 days of entering the 
feedlot; a time of great stress.65 Parainfluenza virus 3 
(Pl-3) typically causes mild to moderate disease, but may 
predispose the lung to secondary, more virulent patho-
gens such as M. haemolytica. 1•3·4·28·35 Bovine and ovine 
respiratory syncytial viruses (RSV) also cause pneumo-
nia and can predispose the lung secondary bacterial in-
fections. 8·27 ·58·59 The mechanism(s) that lead(s) to 
increased lung susceptibility to secondary bacterial in-
fection after an initial viral infection is/are poorly de-
fined. Vaccines to paramyxoviruses and M. haemolytica 
can enhance resistance to infection; however these vac-
cines are not completely effective. 1·2.4·15·19 Despite some 
improvement in managerial practices, vaccines and clini-
·nr. Ackermann was the 2002 Pfizer Excellence in Bovine Research Award winner. 
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cal therapies, M. haemolytica pneumonia remains a 
widespread problem and methods to enhance host re-
sistance to colonization and pneumonia by PI-3/BRSV 
and M. haemolytica are needed. 
Although the defense of the lung is multifactoral 
and complicated, it is reasonable to suspect that alter-
ations in the innate immunity of respiratory epithelial 
cells during and after paramyxoviral pneumonia may 
have at least a partial role in allowing colonization of 
secondary bacteria. Recent work by us and others, par-
ticularly Dr. Gill Diamond, increasingly indicates that 
respiratory epithelia of sheep, cattle and other species, 
produce antimicrobial peptides (AMP), including B-
defensins and anionic peptides, and surfactant protein 
Aand D (SAD) (collectively AMP-SAD), all of which have 
potent microcidal activity.13•22•29•36.45•77 A long-term inter-
est of ours is to develop methods to enhance AMP-SAD 
expression by respiratory epithelia, particularly during 
the neonatal period and at times of stress/shipping. A 
better understanding of AMP-SAD expression and the 
means to enhance their activities is needed because of 
the high incidence ofparamyxoviral andM. haemolytica 
pneumonia in sheep and cattle, the increasing frequency 
of antibiotic resistance, and the general expectation by 
consumers for producers to use antibiotics less fre-
quently. 
PI-3, RSV and Mannheimia haemolytica 
Parainfiuenza virus type 3 (Pl-3). PI-3 infections 
are often subclinical, and can cause fever, coughing, se-
rous nasal and ocular discharge, and dyspnea. Young 
and immunosuppressed animals as well as those under 
stress (overcrowding, shipping) are most susceptible. PI-
3 binds glycoconjugates of epithelial cells via activity of 
the viral hemagglutinin/neuramindase (HNNA), repli-
cates in epithelial cells of the upper respiratory tract, 
and spreads to the lower respiratory tract where it has 
a predilection for bronchiolar epithelial cells.26·60 Re-
infection with PI-3 can occur and secondary infections 
with bacteria are common. Mannheimia (Pasteurella) 
haemolytica, Pasteurella multocida and Haemophilus 
somnus are the most common bacteria isolated from 
calves (and also sheep) infected with PI-3. 1•35•65 In ex-
perimental infections oflambs and calves, PI-3 enhances 
development oflesions when inoculated simultaneously 
or prior to M. haemolytica and leads to decreased alveo-
lar macrophage activity. 28•35 ·80 Human PI-3 decreases 
MHC II expression37 and blocks type I and II interferon 
expression via altered STAT signaling pathways88 , 
thereby inhibiting an active (humoral/cell-mediated) 
immune response, leaving great dependence on innate 
immunity. 
Bovine and ovine respiratory syncytical virus 
(RSV). RSV is a negative sense single-stranded, envel-
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oped RNA virus of the Paramyxoviridae family. 27 •42-44 
Transmission occurs from direct inoculation or large 
aerosol particles into the eye and nose.42-44 Replication 
occurs first in nasopharyngeal epithelium followed by 
replication in the lower respiratory tract. RSV causes 
hyperplasia, necrosis and sloughing of the respiratory 
epithelium with increased mucus production and leu-
kocyte infiltration. This can lead to obstruction of small 
airways and more severe manifestations like tracheo-
bronchitis, bronchiolitis, or pneumonia8·27 ·42-44 as well as 
otitis media. RSV infection is associated with second-
ary bacterial infections. Major RSV envelope glycopro-
teins are the F (fusion) and G (attachment) proteins and 
these induce neutralizing antibodies in the host.20 How-
ever, immunity following infection is not complete nor 
long-lasting, and re-infection in humans occurs fre-
quently irregardless of age. 43 Traditional therapies 
(bronchodilators, steroids, ribavirin) in human patients 
for severe RSV infection generally have no overall sig-
nificant benefit.48 A recently introduced recombinant 
antibody (Palivizumab) to RSV F protein reduced pa-
tient hospitalization, but is not yet cost effective for gen-
eral prophylaxis. 
As indicated, RSV is a globally important respira-
tory disease in cattle, sheep and man. In humans, 
preterm infants and neonates have elevated risks for 
severe RSV infection.43·75 The mechanism(s) for this is 
(are) not well defined; however, infants, compared to 
adults, have a diminished capacity for innate and ac-
quired immune responses.75 Infants have reduced abil-
ity for antibody production and this is partially due to 
the presence of maternal antibodies.67 Furthermore the 
increased risk of bacterial infection in infants is due in 
part to immature neutrophils deficient in antimicrobial 
peptide expression.63 
Mannheimia haemolytica. M. haemolytica (biotype 
A) is one of the most important respiratory pathogens 
of cattle and sheep. 1•4•11 ·15•25 M. haemolytica resides in 
the tonsil and nasal cavity of healthy ruminants and 
undergoes selective proliferation during stress or viral 
infection.34 It can cause serious outbreaks of acute pneu-
monia in neonatal, weaned and growing lambs and adult 
sheep.25 Neonatal and weaned lambs housed together 
are particularly susceptible. Live M. haemolytica vac-
cines can enhance resistance to infection; however these 
vaccines are associated with local tissue reactions, tran-
sient anorexia, fever, and even septicemia. 19·34 Experi-
mental vaccines with partially purified M. haemolytica 
leukotoxin can induce an antibody titer, 19 but the effec-
tiveness in preventing pneumonia has not been fully 
determined. Despite some improvement in managerial 
practices, vaccines and clinical therapies, M. haemolytica 
pneumonia remains a widespread problem and meth-
ods to enhance host resistance to colonization and pneu-
monia by M. haemolytica are needed. 
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Innate Immunity 
The anti-microbial activity ofrespiratory secretions 
were first demonstrated by Alexander Fleming. 32 ·77 He 
later assessed the anti-bacterial activity of lysozyme, 
an important innate immune factor in respiratory se-
cretions. 33 Since then, a wide variety of innate immune 
factors have been identified (Table 1). These factors, 
working in concert with mucociliary clearance, phago-
cytosis by alveolar macrophages, enzyme release by 
neutrophils, and physiologic activity by intravascular 
macrophages, help to protect the respiratory tract 
against microbial colonization and accumulation of par-
ticulate material. More recently, a group of small anti-
microbial peptides and surfactant proteins with potent 
anti-microbial activity at nanogram concentrations have 
become increasingly appreciated for their role in innate 
immunity (Table 1). 
Antimicrobial peptides (AMP) 
of the respiratory tract 
AMP are recently characterized small peptides 
present in epithelial cells, leukocytes and other cells of 
the body. In respiratory tract secretions, many AMP are 
constantly and immediately ready for activity against 
respiratory pathogens. AMP have evolved over the last 
half a billion years, and are present in a wide variety of 
living organisms including plants, insects, and verte-
brates. 77 The major families of AMP in the respiratory 
tract of cattle, sheep and man include the alpha, beta and 
theta defensins, cathelicidins, and anionic peptides. In-
terestingly, AMP of cattle have been on the forefront of 
scientific investigation. The first defensin identified was 
Tracheal Antimicrobial Peptide (TAP), by Dr. Gill Dia-
mond.29·30·77 Dr. Diamond went on to show that TAP was 
produced by respiratory epithelia and its expression could 
be induced by inflammatory stimuli such as IL-1.74 Shortly 
thereafter, Lingual Antimicrobial Peptide (LAP) was iden-
Table 1. Antimicrobial factors in lung surface fluid77. 
tified from the tongue of cattle and 14 other defensins 
were discovered in bovine neutrophils. 77 
Defensins. Defensins are peptides produced by a wide 
range of species76 that have activity against bacteria, vi-
ral and fungal pathogens.41 •45·76 They are small (roughly 
45 amino acids), cationic, and have a diverse primary 
amino acid structure and a more constant secondary and 
tertiary structure.29·77 Defensin families are defined by 
three to four intramolecular cysteine disulfide bonds. 
Based on the location of the cysteine moieties and the dis-
ulfide bonds, the defensins are further classified into al-
pha, beta and theta defensins.6.49 In humans, four 
beta-defensins (HBD-1, HBD-2, HBD-3, HBD-4) have been 
described (Table 2), but up to 28 have been predicted. HBD-
1 is expressed constitutively while HBD-2, 3, and 4 are 
inducible.7·38·39·53 HBD-1 was originally isolated in blood 
filtrate and is expressed in the lung, skin, gastrointesti-
nal and urogenital epithelium.55·69·79 HBD-1 has an im-
portant role in innate pulmonary defense against 
pathogens. In patients with cystic fibrosis, high airway 
salt concentration can render HBD-1 inactive and this may 
predispose the lung to bacterial infection (40). HBD-1 also 
participates in cell regulation by promotion of cell differ-
entiation/maturation in vitro. HBD-1, HBJ:)-2, and 
defensins in general, are thought to exert their antimicro-
bial activity perhaps by forming pores and causing mem-
brane disruption.36•61 Other activities include healing of 
epithelium,68 monocytic, dendritic and T cell chemot-
axis,18·85·87 synergism with other antimicrobial factors such 
as lysozyme and lactoferrin,6 and complement activation. 71 
Recent computerized searches ofhuman and mouse 
chromosomes have found numerous more beta-defensin 
gene sequences in syntenic clusters. 78 The clusters have 
similar gene sequences and organization which suggests 
that each cluster pair arose from a common ancestor 
that was retained because of conserved function. At least 
26 genes in these regions are predicted to be transcribed 
and, therefore, expressed. 78 Such searches may iden-
tify additional beta-defensins of cattle and sheep. 
Factor/product Relative concentration Source 
Lysozyme 
Lactoferrin 
IgA secretory component 
Phospholipase A2 
BPI 
Surfactant proteins A, D (SAD) 
Defensins 
Ca thelicidins 
Anionic peptide 
? denotes uncertainty 
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µg-mg/ml 
µg/ml 
µg/ml 
µg-mg/ml 
? 
ng-µg/mll 
ng-µg/ml 
? 
0.8-1.3 mM 
epithelia, neutrophils 
epithelia, macrophages 
epithelia 
epithelia 
epithelia (?) 
epithelia 
epithelia, neutrophils 
neutrophils, epithelia? 
epithelia 
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Bovine beta-defensins. Both TAP and LAP are ex-
pressed by epithelial cells of the respiratory tract. Their 
expression can be induced by inflammatory stimuli; 
however, TAP expression is much greater than 
LAP. 29·32·74·81 Because of their inductive properties, TAP 
and LAP are increased shortly after initial infection by 
certain respiratory pathogens. We have found that LAP 
expression is markedly increased in calves after infec-
tion with M. haemolytica. 81 TAP expression is increased 
by Gram-negative bacterial components such as li-
popolysaccharide and inflammatory cytokines.29·74 Bio-
logically, the increase of both TAP and LAP may 
significantly contribute to defense against microbial 
pathogens shortly after infection and may then allow 
time for humoral and cell mediated responses. 
Sheep beta-defensin-1 (SBD-1) appears not to be 
induced by infection or inflammatory stimuli (prelimi-
nary findings, not shown) and thus has similar consti-
tutive expression and tissue distribution as HBD-1. 51·52 
SBD-1 expression is developmentally regulated in late 
gestation through the neonatal period with maximal 
expression in some tissues reached weeks after birth.51 
This suggests a window of immature SBD-1 expression 
in the neonate that provides an environment more con-
ducive to severe PI-3, RSV and M. haemolytica infec-
tion. We have found that sheep beta-defensin-2 (SBD-2) 
is also expressed in lung;however, the expression is low. 
Anionic peptide was first isolated from respiratory 
tract of sheep and has potent microcidal activity against 
a wide variety of pathogens.12·15 Anionic peptide is a 
septamer of aspartates, requires zinc as a cofactor for 
bactericidal activity, and is present in pulmonary sur-
factant. Much of the work characterizing anionic pep-
tide was done by Dr. Brogden. Briefly, anionic peptide 
is present in the cytoplasm of individual respiratory epi-
thelial cells of the nasal cavity, trachea, bronchi, bron-
chioles, and alveoli12·15 and also in some submucosal 
gland cells of the trachea of human, ovine and bovine 
lung. In man, anionic peptide differs in concentration 
and location of respiratory tract of healthy patients when 
compared to patients with cystic fibrosis. 14 In sheep, 
we have determined that anionic peptide production 
decreases during acute M. haemoltyica pneumonia in 
sheep and cattle (Table 2). We have also determined 
that during chronic bacterial pneumonia, hyperplastic 
epithelial cells have increased anionic peptide.31 
Cathelicidin SMAP29 of ovine origin sheep has very 
potent activity against respiratory pathogens. 16 
Cathelicidins are often expressed by neutrophils72·90 and 
cattle, sheep, goats and man expression a number of 
cathelicidin peptides.72 Some studies have suggested that 
some cathelicidins are expressed by respiratory epithe-
lia29·77 of humans; however, expression in the respiratory 
tract of cathelicidin in sheep and cattle have not been 
fully characterized. 72 
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Surfactant proteins with antimicrobial activity 
Surfactant proteins A & D (SAD) are calcium-de-
pendent lectins and members of the collectin fam-
ily. 21·24·57·89 SAD expression and function are primarily 
studied in the lung; however, extrapulmonary expres-
sion has been detected elsewhere including the Eusta-
chian tube.57·70·83 In the lung, SAD are expressed by 
type-II pneumocytes and Clara cells;23 however, surfac-
tant protein A has two transcripts, one of which is ex-
pressed by submucosal glands of large airways. SAD 
have an important role in immunomodulation, surfac-
tant homeostasis, and pulmonary defense.21·22·57 SAD 
interact with bacterial, fungal and viral pathogens by 
binding and forming aggregates. 21·47 The SAD aggre-
gates can inactivate the pathogen,47·84 stimulate phago-
cytosis,73 enhance antigen presentation10 and potentiate 
oxidant responses ofneutrophils,9 Developmentally, con-
stitutive expression of SAD in the rat increases late in 
gestation and through the neonatal period.24 Deficiency 
of SAD in vivo is associated with increased risk for in-
fection, 5 and enhanced inflammation and inflammatory 
cell recruitment during infection.62 SAD can reduce RSV 
infection.47·48·56·57·62 Severe RSV infection in infants is 
associated with reduced SAD in the bronchoalveolar 
lavage (BAL).56 In mice, SAD inhibit RSV infection in 
vivo and play a major role in clearance from the 
lungs.47·57·62 SAD are similar in man and sheep.22·57·64 
We have found that SAD appears to be decreased in bron-
chioles undergoing hyperplasia during chronic pneumo-
nia (unpublished observations). Such an alteration in 
SAD expression may allow chronic infections to persist 
and/or secondary infections to become established in 
already diseased lungs. 
Conclusions 
Our long-term goal is to better understand the in-
nate immune system in order to reduce or prevent disease 
in neonates and in older animals at times of stress (wean-
ing, shipping, overcrowding, inclement weather, etc.). This 
may be difficult, because it is clear that innate immune 
factors , including AMP-SAD, are not fully effective in pre-
venting respiratory tract infections in normal animals, 
since we already know that they express AMP-SAD and 
infections occur anyway. However, it is equally clear that 
humoral and cell mediated immune responses are also not 
fully effective, since animals with normal antibody and 
cell-mediated responses also acquire infections. Since the 
time of Jenner and Pasteur, vaccines against microbial 
pathogens have been developed and refined, yet respira-
tory disease and pneumonia remain major health prob-
lems. Thus , a multi-factorial strategy that includes 
adequate management, nutrition, housing, ventilation, and 
optimal activity of all aspects of the immune system, in-
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eluding innate, humoral, and cell-mediated responses, 
appears reasonable. In the meantime, defining and un-
derstanding the mechanistic basis of AMP-SAD expres-
sion may be useful in making such strategies possible. 
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Introduction 
Leptin is being investigated as a necessary compo-
nent to attain reproductive efficiency in beef cattle. The 
effect offeeding monensin on leptin levels at puberty sheds 
light on the mechanism of action ofleptin. Cows that calve 
early in the breeding season or have a calving interval of 
twelve months or less are more profitable than cows with 
longer calving intervals. For each 21-day heat-cycle a cow 
is late calving, her calf will weigh about 40 lb less.at wean-
ing. Cows that calve early in the breeding season as heif-
ers will be more likely to calve early as cows, and in order 
for heifers to calve early, they must reach puberty early. 
The selection and management of replacement heifers 
influences the reproductive efficiency of the cattle indus-
try by optimizing age at puberty. Heifers that mature 
sexually at an early age are more likely to settle earlier 
in a controlled breeding season and wean a heavier calf. 
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These heifers tend to settle early each breeding season 
for the rest of their reproductive lives and have heavier 
weaning weights throughout their lifetime. 
With this economic value placed on reproduction, 
ways to measure, improve and predict reproductive effi-
ciency in cattle are critically important. Age, nutritional 
status and genetics are factors that control the onset of 
puberty in beef heifers. Nutritional status of beef heifers 
and reproduction are intimately related. A target weight 
of 65% of mature weight at breeding is critical for a suc-
cessful breeding program. Monensin is an ionophore feed 
supplement used to increase weight gain and decrease 
age at puberty in beef and dairy heifers. The mechanism 
of action to decrease age at puberty has not been fully 
determined. Pre-pubertal heifers fed monensin produced 
larger corpora lutea, larger follicles and exhibited in-
creased response to administration of gonadotropins com-
pared to control heifers fed to achieve equal weight gains. 
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